(LEGN) Legend Biotech - Ratings and Ratios
CAR-T, BCMA, Gamma-Delta, Autologous, Multiple-Myeloma
LEGN EPS (Earnings per Share)
LEGN Revenue
Description: LEGN Legend Biotech
Legend Biotech Corp (NASDAQ:LEGN) is a biopharmaceutical company that focuses on developing and commercializing novel cell therapies, particularly CAR-T therapies, for various cancers, including multiple myeloma, Non-Hodgkins Lymphoma, and other indications. The companys lead product candidate, cilta-cel, is a CAR-T therapy for multiple myeloma, developed in collaboration with Janssen Biotech, Inc.
To evaluate Legend Biotechs performance, key performance indicators (KPIs) such as revenue growth, R&D expenses as a percentage of revenue, and cash burn rate are essential. Given the companys current stage, its likely that R&D expenses are a significant portion of its total expenses. The companys collaboration with Janssen Biotech and license agreement with Novartis Pharma AG are crucial for its growth prospects.
From a financial perspective, Legend Biotechs market capitalization is approximately $8.16 billion, with a forward P/E ratio of 1000, indicating high growth expectations. The companys return on equity (RoE) is -20.14%, which is expected given its stage of development and significant investment in R&D. To gauge the companys financial health, its essential to monitor its cash reserves, operating expenses, and cash flow from operations.
To further assess Legend Biotechs potential, its crucial to track the progress of its pipeline products, including cilta-cel and other CAR-T therapies, through various stages of clinical trials. The companys ability to successfully commercialize its products, manage costs, and maintain strategic partnerships will be vital to its long-term success.
LEGN Stock Overview
| Market Cap in USD | 6,659m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2020-06-05 |
LEGN Stock Ratings
| Growth Rating | -25.4% |
| Fundamental | 32.9% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -43.2% |
| Analyst Rating | 4.45 of 5 |
LEGN Dividends
Currently no dividends paidLEGN Growth Ratios
| Growth Correlation 3m | -29.8% |
| Growth Correlation 12m | -45.4% |
| Growth Correlation 5y | 23.6% |
| CAGR 5y | -4.83% |
| CAGR/Max DD 3y | -0.08 |
| CAGR/Mean DD 3y | -0.19 |
| Sharpe Ratio 12m | -1.54 |
| Alpha | 0.04 |
| Beta | 0.573 |
| Volatility | 44.03% |
| Current Volume | 1120.9k |
| Average Volume 20d | 956.1k |
| Stop Loss | 32.8 (-4.8%) |
| Signal | -0.25 |
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income (-325.8m TTM) > 0 and > 6% of Revenue (6% = 47.9m TTM) |
| FCFTA -0.09 (>2.0%) and ΔFCFTA 13.78pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 123.4% (prev 247.9%; Δ -124.5pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.16 (>3.0%) and CFO -274.7m > Net Income -325.8m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 4.71 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (92.1m) change vs 12m ago 0.84% (target <= -2.0% for YES) |
| Gross Margin 61.77% (prev 57.85%; Δ 3.92pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 45.74% (prev 25.36%; Δ 20.38pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -13.54 (EBITDA TTM -260.4m / Interest Expense TTM 21.0m) >= 6 (WARN >= 3) |
Altman Z'' -3.98
| (A) 0.58 = (Total Current Assets 1.25b - Total Current Liabilities 265.5m) / Total Assets 1.69b |
| (B) -1.12 = Retained Earnings (Balance) -1.89b / Total Assets 1.69b |
| warn (B) unusual magnitude: -1.12 — check mapping/units |
| (C) -0.16 = EBIT TTM -283.8m / Avg Total Assets 1.74b |
| (D) -2.92 = Book Value of Equity -1.89b / Total Liabilities 647.5m |
| Total Rating: -3.98 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 32.91
| 1. Piotroski 2.0pt = -3.0 |
| 2. FCF Yield -2.63% = -1.32 |
| 3. FCF Margin -19.82% = -7.43 |
| 4. Debt/Equity 0.31 = 2.45 |
| 5. Debt/Ebitda -1.21 = -2.50 |
| 6. ROIC - WACC (= -28.75)% = -12.50 |
| 7. RoE -30.95% = -2.50 |
| 8. Rev. Trend 95.92% = 7.19 |
| 9. EPS Trend 50.16% = 2.51 |
What is the price of LEGN shares?
Over the past week, the price has changed by +2.99%, over one month by -7.96%, over three months by -0.66% and over the past year by -32.64%.
Is Legend Biotech a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of LEGN is around 29.89 USD . This means that LEGN is currently overvalued and has a potential downside of -13.29%.
Is LEGN a buy, sell or hold?
- Strong Buy: 11
- Buy: 10
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the LEGN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 77.3 | 124.2% |
| Analysts Target Price | 77.3 | 124.2% |
| ValueRay Target Price | 33.1 | -3.9% |
Last update: 2025-09-08 04:43
LEGN Fundamental Data Overview
CCE Cash And Equivalents = 967.6m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 21.7391
P/S = 8.3572
P/B = 6.4308
Beta = 0.284
Revenue TTM = 797.7m USD
EBIT TTM = -283.8m USD
EBITDA TTM = -260.4m USD
Long Term Debt = 310.3m USD (from longTermDebt, last quarter)
Short Term Debt = 5.91m USD (from shortTermDebt, last quarter)
Debt = 316.2m USD (Calculated: Short Term 5.91m + Long Term 310.3m)
Net Debt = 121.3m USD (from netDebt column, last quarter)
Enterprise Value = 6.01b USD (6.66b + Debt 316.2m - CCE 967.6m)
Interest Coverage Ratio = -13.54 (Ebit TTM -283.8m / Interest Expense TTM 21.0m)
FCF Yield = -2.63% (FCF TTM -158.1m / Enterprise Value 6.01b)
FCF Margin = -19.82% (FCF TTM -158.1m / Revenue TTM 797.7m)
Net Margin = -40.84% (Net Income TTM -325.8m / Revenue TTM 797.7m)
Gross Margin = 61.77% ((Revenue TTM 797.7m - Cost of Revenue TTM 304.9m) / Revenue TTM)
Tobins Q-Ratio = -3.18 (set to none) (Enterprise Value 6.01b / Book Value Of Equity -1.89b)
Interest Expense / Debt = 1.66% (Interest Expense 5.24m / Debt 316.2m)
Taxrate = 21.0% (US default)
NOPAT = -283.8m (EBIT -283.8m, no tax applied on loss)
Current Ratio = 4.71 (Total Current Assets 1.25b / Total Current Liabilities 265.5m)
Debt / Equity = 0.31 (Debt 316.2m / last Quarter total Stockholder Equity 1.04b)
Debt / EBITDA = -1.21 (Net Debt 121.3m / EBITDA -260.4m)
Debt / FCF = -2.00 (Debt 316.2m / FCF TTM -158.1m)
Total Stockholder Equity = 1.05b (last 4 quarters mean)
RoA = -19.28% (Net Income -325.8m, Total Assets 1.69b )
RoE = -30.95% (Net Income TTM -325.8m / Total Stockholder Equity 1.05b)
RoCE = -20.82% (Ebit -283.8m / (Equity 1.05b + L.T.Debt 310.3m))
RoIC = -20.93% (NOPAT -283.8m / Invested Capital 1.36b)
WACC = 7.82% (E(6.66b)/V(6.98b) * Re(8.13%)) + (D(316.2m)/V(6.98b) * Rd(1.66%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 1.46%
Discount Rate = 8.13% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -158.1m)
EPS Correlation: 50.16 | EPS CAGR: 15.62% | SUE: 0.41 | # QB: 0
Revenue Correlation: 95.92 | Revenue CAGR: 125.5% | SUE: -0.84 | # QB: 0
Additional Sources for LEGN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle